4D Molecular Therapeutics Announces First Patients Enrolled In Phase 3 Trial Of 4D-150 In Diabetic Macular Edema; 2-Year Data Show 61% Fewer Injections
Share
Why It Matters
A company testing a new eye medicine got its first patients enrolled. The medicine might need far fewer shots, which is better for patients.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.